Literature DB >> 29661916

Sustained Reduction in Severe Hypoglycemia in Adults With Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia: Two-Year Follow-up in the HypoCOMPaSS Randomized Clinical Trial.

Stuart A Little1,2, Jane Speight3,4,5, Lalantha Leelarathna6, Emma Walkinshaw7, Horng Kai Tan8, Anita Bowes9, Alexandra Lubina-Solomon7, Thomas J Chadwick10, Deborah D Stocken10, Catherine Brennand11, Sally M Marshall1,2, Ruth Wood11, David Kerr9, Daniel Flanagan8, Simon R Heller7, Mark L Evans6, James A M Shaw12,2.   

Abstract

OBJECTIVE: Severe hypoglycemia is a feared complication of type 1 diabetes; yet, few trials have targeted prevention using optimized self-management (educational, therapeutic, and technological support). We aimed to investigate whether improved awareness and reduced severe hypoglycemia, achieved during an intensive randomized clinical trial (RCT), were sustained after return to routine care. RESEARCH DESIGN AND METHODS: Ninety-six adults with type 1 diabetes (29 ± 12 years' duration) and impaired awareness of hypoglycemia at five U.K. tertiary referral diabetes centers were recruited into a 24-week 2 × 2 factorial RCT (HypoCOMPaSS). Participants were randomized to pump (continuous subcutaneous insulin infusion [CSII]) or multiple daily injections (MDIs) and real-time continuous glucose monitoring (RT-CGM) or self-monitoring of blood glucose (SMBG), with equal education/attention to all groups. At 24 weeks, participants returned to routine care with follow-up until 24 months, including free choice of MDI/CSII; RT-CGM vs. SMBG comparison continued to 24 months. Primary outcome was mean difference (baseline to 24 months [between groups]) in hypoglycemia awareness.
RESULTS: Improvement in hypoglycemia awareness was sustained (Gold score at baseline 5.1 ± 1.1 vs. 24 months 3.7 ± 1.9; P < 0.0001). Severe hypoglycemia rate was reduced from 8.9 ± 12.8 episodes/person-year over the 12 months prestudy to 0.4 ± 0.8 over 24 months (P < 0.0001). HbA1c improved (baseline 8.2 ± 3.2% [66 ± 12 mmol/mol] vs. 24 months 7.7 ± 3.1% [61 ± 10 mmol/mol]; P = 0.003). Improvement in treatment satisfaction and reduced fear of hypoglycemia were sustained. There were no significant differences between interventions at 24 months.
CONCLUSIONS: Optimized insulin replacement and glucose monitoring underpinned by hypoglycemia-focused structured education should be provided to all with type 1 diabetes complicated by impaired awareness of hypoglycemia.
© 2018 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29661916     DOI: 10.2337/dc17-2682

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  14 in total

Review 1.  Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology.

Authors:  Paola Lucidi; Francesca Porcellati; Geremia B Bolli; Carmine G Fanelli
Journal:  Curr Diab Rep       Date:  2018-08-18       Impact factor: 4.810

2.  Real-World Experience With Automated Insulin Pump Technology in Veterans With Type 1 Diabetes.

Authors:  Morolake Amole; Loren Whyte; Hans K Ghayee; Fernando Bril; Kenneth Cusi; Julio Leey-Casella
Journal:  Fed Pract       Date:  2021-11

3.  The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Richard I G Holt; J Hans DeVries; Amy Hess-Fischl; Irl B Hirsch; M Sue Kirkman; Tomasz Klupa; Barbara Ludwig; Kirsten Nørgaard; Jeremy Pettus; Eric Renard; Jay S Skyler; Frank J Snoek; Ruth S Weinstock; Anne L Peters
Journal:  Diabetologia       Date:  2021-12       Impact factor: 10.122

4.  Factors associated with favourable 5 year outcomes in islet transplant alone recipients with type 1 diabetes complicated by severe hypoglycaemia in the Collaborative Islet Transplant Registry.

Authors:  Bernhard J Hering; Cassandra M Ballou; Melena D Bellin; Elizabeth H Payne; Fouad Kandeel; Piotr Witkowski; Rodolfo Alejandro; Michael R Rickels; Franca B Barton
Journal:  Diabetologia       Date:  2022-10-06       Impact factor: 10.460

5.  Flash glucose monitoring improves glycemia in higher risk patients: a longitudinal, observational study under real-life settings.

Authors:  Sujit Jangam; Timothy Dunn; Yongjin Xu; Gary Hayter; Ramzi A Ajjan
Journal:  BMJ Open Diabetes Res Care       Date:  2019-03-25

Review 6.  Advanced Technology in the Management of Diabetes: Which Comes First-Continuous Glucose Monitor or Insulin Pump?

Authors:  Christopher T Martin; Amy B Criego; Anders L Carlson; Richard M Bergenstal
Journal:  Curr Diab Rep       Date:  2019-06-27       Impact factor: 4.810

Review 7.  The road from intermittently scanned continuous glucose monitoring to hybrid closed-loop systems. Part B: results from randomized controlled trials.

Authors:  Francesca De Ridder; Marieke den Brinker; Christophe De Block
Journal:  Ther Adv Endocrinol Metab       Date:  2019-08-30       Impact factor: 3.565

8.  Effectiveness and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A protocol for Systematic review and Meta-analysis.

Authors:  Mao-Bing Chen; Rui-Jun Xu; Qi-Han Zheng; Xu-Wen Zheng; Hua Wang; Yun-Long Ding; Mao-Xing Yue
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

9.  Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia Prevention.

Authors:  Anna R Kahkoska; John B Buse
Journal:  Diabetes Care       Date:  2018-08       Impact factor: 19.112

10.  2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association.

Authors:  Kyu Yeon Hur; Min Kyong Moon; Jong Suk Park; Soo-Kyung Kim; Seung-Hwan Lee; Jae-Seung Yun; Jong Ha Baek; Junghyun Noh; Byung-Wan Lee; Tae Jung Oh; Suk Chon; Ye Seul Yang; Jang Won Son; Jong Han Choi; Kee Ho Song; Nam Hoon Kim; Sang Yong Kim; Jin Wha Kim; Sang Youl Rhee; You-Bin Lee; Sang-Man Jin; Jae Hyeon Kim; Chong Hwa Kim; Dae Jung Kim; SungWan Chun; Eun-Jung Rhee; Hyun Min Kim; Hyun Jung Kim; Donghyun Jee; Jae Hyun Kim; Won Seok Choi; Eun-Young Lee; Kun-Ho Yoon; Seung-Hyun Ko
Journal:  Diabetes Metab J       Date:  2021-07-30       Impact factor: 5.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.